Mettler-Toledo International Inc. (0K10.L)
USD 1248.03
(-0.62%)
USD 1248.03
(-0.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.08 Billion USD | -3.46% |
| 2022 | 1.12 Billion USD | 13.22% |
| 2021 | 994.73 Million USD | 26.87% |
| 2020 | 784.04 Million USD | 7.64% |
| 2019 | 728.38 Million USD | 6.65% |
| 2018 | 682.98 Million USD | 11.98% |
| 2017 | 609.91 Million USD | 12.91% |
| 2016 | 540.18 Million USD | 5.16% |
| 2015 | 513.68 Million USD | 7.54% |
| 2014 | 477.68 Million USD | 6.54% |
| 2013 | 448.35 Million USD | 5.96% |
| 2012 | 423.14 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 267.74 Million USD | 7.49% |
| 2024 Q1 | 249.1 Million USD | -5.54% |
| 2023 Q3 | 277.65 Million USD | -4.15% |
| 2023 Q1 | 248.67 Million USD | -27.3% |
| 2023 Q4 | 263.69 Million USD | -5.03% |
| 2023 Q2 | 289.66 Million USD | 16.48% |
| 2023 FY | 1.07 Billion USD | -4.13% |
| 2022 FY | 1.12 Billion USD | 13.22% |
| 2022 Q3 | 290.44 Million USD | 7.94% |
| 2022 Q2 | 269.06 Million USD | 19.78% |
| 2022 Q1 | 224.64 Million USD | -25.65% |
| 2022 Q4 | 342.07 Million USD | 17.78% |
| 2021 Q3 | 256.77 Million USD | 7.42% |
| 2021 Q4 | 302.13 Million USD | 17.67% |
| 2021 Q1 | 196.78 Million USD | -30.05% |
| 2021 Q2 | 239.03 Million USD | 21.47% |
| 2021 FY | 994.73 Million USD | 26.87% |
| 2020 Q2 | 165.7 Million USD | 27.2% |
| 2020 Q4 | 281.31 Million USD | 28.48% |
| 2020 FY | 784.04 Million USD | 7.64% |
| 2020 Q1 | 130.26 Million USD | -46.77% |
| 2020 Q3 | 218.95 Million USD | 32.14% |
| 2019 FY | 728.38 Million USD | 6.65% |
| 2019 Q4 | 244.72 Million USD | 32.21% |
| 2019 Q3 | 185.1 Million USD | 11.12% |
| 2019 Q2 | 166.57 Million USD | 21.78% |
| 2019 Q1 | 136.78 Million USD | -40.34% |
| 2018 Q1 | 129.41 Million USD | -37.22% |
| 2018 Q3 | 171.66 Million USD | 8.08% |
| 2018 FY | 682.98 Million USD | 11.98% |
| 2018 Q2 | 158.84 Million USD | 22.73% |
| 2018 Q4 | 229.25 Million USD | 33.54% |
| 2017 FY | 609.91 Million USD | 12.91% |
| 2017 Q2 | 137.15 Million USD | 17.74% |
| 2017 Q4 | 206.15 Million USD | 35.45% |
| 2017 Q3 | 152.2 Million USD | 10.97% |
| 2017 Q1 | 116.48 Million USD | -38.8% |
| 2016 Q4 | 190.34 Million USD | 33.49% |
| 2016 FY | 540.18 Million USD | 5.16% |
| 2016 Q3 | 142.58 Million USD | 18.41% |
| 2016 Q2 | 120.42 Million USD | 28.67% |
| 2016 Q1 | 93.58 Million USD | -46.27% |
| 2015 Q2 | 110.67 Million USD | 23.28% |
| 2015 Q3 | 126.5 Million USD | 14.3% |
| 2015 FY | 513.68 Million USD | 7.54% |
| 2015 Q1 | 89.77 Million USD | -46.77% |
| 2015 Q4 | 174.19 Million USD | 37.7% |
| 2014 Q4 | 168.66 Million USD | 41.14% |
| 2014 FY | 477.68 Million USD | 6.54% |
| 2014 Q1 | 83.85 Million USD | -46.94% |
| 2014 Q2 | 105.66 Million USD | 26.0% |
| 2014 Q3 | 119.5 Million USD | 13.1% |
| 2013 Q2 | 100.59 Million USD | 25.26% |
| 2013 Q3 | 109.4 Million USD | 8.75% |
| 2013 Q4 | 158.03 Million USD | 44.45% |
| 2013 FY | 448.35 Million USD | 5.96% |
| 2013 Q1 | 80.31 Million USD | -45.67% |
| 2012 FY | 423.14 Million USD | 0.0% |
| 2012 Q4 | 147.82 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 742.674% |
| Dynavax Technologies Corporation | -37.02 Million USD | 3036.381% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 20735.472% |
| Perrigo Company plc | 151.9 Million USD | -615.789% |
| Illumina, Inc. | -1.06 Billion USD | 201.71% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 84.148% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 336.079% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 107.724% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 45.003% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 1082.944% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 73.134% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 2534.198% |
| Waters Corporation | 817.67 Million USD | -32.972% |
| Biogen Inc. | 1.29 Billion USD | 16.156% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 496.811% |
| Evolus, Inc. | -49.23 Million USD | 2308.444% |
| Adicet Bio, Inc. | -152.03 Million USD | 815.139% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 994.92% |
| bluebird bio, Inc. | -244.26 Million USD | 545.13% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 798.934% |
| FibroGen, Inc. | -281.81 Million USD | 485.814% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 19.461% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 2512.041% |
| Homology Medicines, Inc. | -48.25 Million USD | 2353.203% |
| Geron Corporation | -193.94 Million USD | 660.617% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 485.322% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 1579.417% |
| Myriad Genetics, Inc. | -123.7 Million USD | 978.968% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1178.365% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 311.004% |
| Zoetis Inc. | 3.06 Billion USD | 64.572% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 2355.774% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -459.184% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 74.758% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 2877.011% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 407.377% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 493.935% |
| Verastem, Inc. | -92.08 Million USD | 1280.751% |
| Nektar Therapeutics | -137.42 Million USD | 891.183% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 569.01% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 1216.8% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 505.969% |
| OPKO Health, Inc. | -157.02 Million USD | 792.444% |
| Exelixis, Inc. | 170.88 Million USD | -536.266% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -333.353% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -913.481% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 2050.074% |
| uniQure N.V. | -282.87 Million USD | 484.374% |
| Imunon, Inc. | -21.03 Million USD | 5270.046% |
| Blueprint Medicines Corporation | -486.27 Million USD | 323.593% |
| Insmed Incorporated | -709.62 Million USD | 253.219% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -222.087% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 377.732% |
| TG Therapeutics, Inc. | 20.63 Million USD | -5169.631% |
| Incyte Corporation | 620.52 Million USD | -75.22% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 249.681% |